--ARCHIVE_PAGE_LINK--
 
 
 
 
 
DECEMBER  13 , 2019
 
 
 
KNOW It 2020 LV
 
 
Quick Links
 
 
 

 
Wellness Momentum
 
 

 
Momentum Wellness Summit
NatLawReview Newsletters
 
 
Cannabis, Biotech, Food and Drug Legal News
In house attorneys looking for a better way to organize, vet and easily retrieve legal news created the National Law Review on-line edition.

Around the clock, the National Law Review's editors screen and classify breaking news and analysis authored by recognized legal professionals and our own journalists.

There is no log in to access the database and new articles are added hourly.
 
 
 
 
What is Zantac (ranitidine)?
You have seen a lot of commercials and have probably been searching the internet for some straightforward explanations about Zantac Cancer Lawsuits and Settlements.
Very simply, Zantac is the brand name of a common heartburn medication called ranitidine. Zantac (ranitidine) is a type of drug known as an H2 blocker, or H2 antagonist, which decreases stomach acid by blocking histamine receptors in the stomach. It can be used to treat peptic ulcers, gastroesophageal reflux disease, and related conditions. More on Zantac Cancer Lawsuits Here  >
 
 
 
On November 6, 2019, the bonds between the U.S. government and pharmaceutical companies were stretched when the U.S. Department of Health and Human Services (“HHS”) filed a patent infringement lawsuit against Gilead Sciences in Delaware federal court regarding Gilead’s popular HIV drugs, Truvada® and Descovy®.  HHS rarely sues for patent infringement.  In fact, the U.S. government and pharmaceutical companies typically have collaborative relationships.  For example, Gilead provided the Center for Disease Control and Prevention (“CDC”) with free drugs for government experiments to expand treatment for certain diseases.  So, what happened?  More on the HHS HIV Drug Lawsuit Here >
 
 
 
As we previously reported in “Illinois’ Legalization of Marijuana May Change the Drug-Free Workplace Landscape,” Illinois’ Cannabis Regulation and Tax Act (the “CRTA”) will legalize recreational marijuana effective January 1, 2020. Since the CRTA’s passage in mid-2019, employers in Illinois have grappled with how to maintain compliance both with the law and their drug-free workplace policies. On December 4, 2019, however, Governor J.B. Pritzker signed legislation amending the CRTA. The amendments may allow employers to breathe a little easier come the first of the year. More on Illinois' Recreational Marijuana Law Amendments Here >
 
 
 
There is less than one month before the effective date of the online requirements set forth in California’s Cleaning Product Right to Know Act of 2017 (S.B. 258). S.B. 258 sets forth new requirements on manufacturers of “designated products” to disclose certain chemical ingredients on the manufacturer’s website and product label. The online ingredient disclosure requirements set forth under California’s law are applicable to designated products sold in California as of January 1, 2020.   More on California's Online Disclosure Requirements for Cleaning Products Here >
 
 
 
 
Please let other interested professionals know about this valuable and free resource!

If you know someone interested in publishing with the National Law Review, kindly contact us at:
   
The National Law Review
National Law Forum, LLC
Jennifer Schaller, Esq.
 
 
SCCE Workshops 2020
 
 
NLR Publication Areas
 
 
 
 
 
 
 
 
 
 
 
 
​​​​
 
 
 
The National Law Review
 708-357-3317 | jschaller@natlawreview.com | www.natlawreview.com
4700 Gilbert Avenue Suite #47 #230
Western Springs, IL 60558